Table 1.
Baseline characteristics of the study population
| Total population: n = 80 subjects | Non-infected n = 67 (83.8%) |
Convalescent n = 13 (16.2%) |
||
|---|---|---|---|---|
| Sex | ||||
| Female n(%) | 56 | (83.6) | 11 | (84.6) |
| Male n(%) | 11 | (16.4) | 2 | (15.4) |
| Age (years) | ||||
| ≤ 45 n(%) | 26 | (38.8) | 6 | (46.2) |
| 46–65 n(%) | 15 | (22.4) | 5 | (38.4) |
| ≥ 66 n(%) | 26 | (38.8) | 2 | (15.4) |
| Median [IQR] | 52 | [34–84] | 54 | [36–60] |
| Type of primary vaccination | ||||
| Homologous BNT162b2 n(%) | 38 | (56.7) | 6 | (46.2) |
| Homologous mRNA-1273 n(%) | 18 | (26.9) | 7 | (53.8) |
| Homologous AZD1222 n(%) | 1 | (1.5) | / | / |
| Heterologous AZD1222/BNT162b2 n(%) | 1 | (1.5) | / | / |
| Heterologous AZD1222/mRNA-1273 n(%) | 9 | (13.4) | / | / |
| Sampling time | ||||
| T0 n(%) | 16 | (23.9) | 10 | (76.9) |
| T1 n(%) | 46 | (68.7) | 13 | (100.0) |
| T2 n(%) | 67 | (100.0) | / | / |
| T3 n(%) | 31 | (46.2) | / | / |
| Total | 160 | 23 | ||
Type of vaccine: BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), AZD1222 (Oxford-AstraZeneca); sampling time: T0, before vaccination; T1, 2–4 weeks after the first dose; T2, 2–4 weeks after the second dose; T3, 2–4 weeks after the third dose.